MSD has opened the doors of a $1 billion manufacturing facility at its site in Durham, North Carolina, that will be used to produce the bulk drug substance for its HPV vaccine Gardasil.

The China National Medical Products Administration (NMPA) has granted expanded approval to MSD's GARDASIL, [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for use ...